期刊文献+

树突状细胞联合化疗治疗老年人晚期恶性肿瘤的临床观察 被引量:1

Clinical observation of dendritic cell vaccination combined with chemotherapy in elderly patients with advanced malignant tumor
下载PDF
导出
摘要 目的:探讨同源异体肿瘤抗原致敏的树突状细胞联合化疗治疗中老人晚期恶性肿瘤的临床疗效、不良反应。方法:对开展树突状细胞体外培养技术以来,联合化疗治疗经细胞学或病理学确诊的晚期或复发肿瘤25例,分离患者外周血单核细胞和淋巴细胞在体外培养成树突状细胞(dendritic cell DC),化疗结束后行树突状细胞治疗,观察指标有客观缓解率、临床获益率和不良反应。结果:25例中有2例达CR,4例达PR,2例MR,SD 11例,无效2例,4例PD,未发现Ⅲ级以上的不良反应。结论:树突状细胞联合化疗治疗老年肿瘤患者安全性好,能降低化疗的不良反应,并改善患者的临床症状,提高免疫功能,改善生存质量。 Objective:To study the clinical effect and adverse reaction of dendritic cell (DC) vaccination combined with chemotherapy in elderly patients with advanced malignant tumor.Methods:25 elderly patients with advanced or recurrent malignant tumor confirmed by cytology or pathology were enrolled since 2005,matured DCs were derived from peripheral blood monocytes and loaded tumor lysate, DCs were injected in a lymph mode and intromitted by peripheral vessel after chemotherapy.The objective remission rate,tumor marker profde and adverse reaction were determined respectively.Results:The therapy resulted in 2 cases complete remission,4 partial remission,2 minal remission,11 stable disease,2 no change and 4 progressive disease.The serious adverse reaction was not found.Conclusion:Dendritic cell vaccination combined with chemotherapy in elderly patients with advanced malignant tumor is an affective and safe comprehensive method,and can decrease the adverse reaction of chemotherapy,enhance the immune function and improve the quality of life.
出处 《现代医药卫生》 2007年第1期9-11,共3页 Journal of Modern Medicine & Health
关键词 树突状细胞 化疗 老年人 肿瘤 Dendritic cell Chemotherapy Old people Tumor
  • 引文网络
  • 相关文献

参考文献5

  • 1罗荣城,尤长宣.肿瘤生物治疗新进展[J].中国新药杂志,2005,14(2):143-146. 被引量:18
  • 2Chiyo M,Shimosato O,Yu L ,et al.Expression of IL-27 in Murine carcinama cells produces antitumor effects and induces protective immunity in inocutaled host animal[J].Int J Cancer,2005,115(3):437.
  • 3冷松,韩秀敏,王若雨,吕申,张阳.体内致敏的树突状细胞诱导特异性抗肿瘤免疫的基础研究[J].中国微生态学杂志,2006,18(2):94-97. 被引量:1
  • 4Hirschowitz EA,Foody T,Kryscio R,et al.Autologous dendritic cell vaccines for non-small-cell lung cancer[J].Clin Oncol,2004,22(14):2808.
  • 5weihrauch MR,Ansen S,Jurkiewicz E. Phase Ⅰ/Ⅱ combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide andpatients with primary metastatic colorectal cance[J].Clin Cancer Res,2005,11(16):5993.

二级参考文献25

  • 1Liu Y, Chiriva-Internati M, You C, et al. Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-selfcytotoxic T lymphocytes by recombinant adeno-associated virusbased gene loading of dendritic cells [ J ]. Cancer Gene Ther,2005,12(3) :304 - 312.
  • 2Midgley R, Kerr DJ, Mirza N, et al. A phase Ⅱ dendritic cell (DC) immunotherapy trial for hepatocellular carcinoma (HC) [J]. Proc Am Soc Clin Oncol,2002,21:23b.
  • 3Chang JWC,Hsieh JJ,Chen J S, et al. Immunotherapy with dendritic cells pulsed by autologous dactinomycin-treated melanoma apoptotic cells for patients with malignant melanoma [ J ]. ProcAm Soc Clin Oncol,2002,21:3b.
  • 4Chiriva-Internati M, Liu Y, Salati E, et al. Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells[J ]. Eur J Immunol, 2002,32(1) :30 - 38.
  • 5Slichenmyer WJ,Fry DW. Anticancer therapy targeting the erbB family of receptor tyrosine kinases[J]. Semin Oncol, 2001,28 (Suppl 16) :S67 - S79.
  • 6Hainsworth JD, Litchy S, Burris HA, et al. Rituximab as firstline and maintenance therapy for patients with indolent nonhodgkin's lymphoma[J]. J Clin Oncol,2002,20(20):4261 -4267.
  • 7Cohen RB. Epidermal growth factor receptor as a therapeutic target in colorectal cancer[J]. Clin Colorectal Cancer ,2003,2(4): 246 - 251.
  • 8Goodman L. Persistance-luck-Avastin[J]. J Clin Invest,2004, 113(7) :934 - 940.
  • 9Van Oosterom AT, Judson I, Verweij J, et al. STI 571, an active drug in metastatic gastro-intestinal stromal tumors (GIST), an EORTC phase Ⅰ study[J]. Proc Am Soc Clin Oncol,2001,20 : 1 a.
  • 10Fukuora M, Yano S, Giaccone G, et al. Final results from a phase Ⅱ trial of ZD1839(Iressa) for patients with advanced non-smallcell lung cancer ( IDEAL. 1 ) [ J ]. Proc Am Soc Clin Oncol, 2003,22: 298a.

共引文献17

同被引文献7

引证文献1

二级引证文献4

;
使用帮助 返回顶部